A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
Inclusion Criteria:
Exclusion Criteria:
Fort Gratiot, Michigan 48059, United States
Lebanon, New Hampshire 03756, United States
Chapel Hill, North Carolina 27514, United States
Wiesbaden/ Bierstadt, 65191, Germany
Witten, 58453, Germany
Niao-Sung Hsiang, Kaohsiung County 833, Taiwan
Kwei-Shan, Taoyuan 333, Taiwan
Kyiv, 01032, Ukraine